StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3078% above fair value
$17.58−0.96 (-5.18%)

Close on Nov 20, 2026Market cap $4.97BP/E –Yield –

Caris Life Sciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Caris Life Sciences's free cash flow for the twelve months ending Sep 30, 2026 was $28.91M. For fiscal 2025 it was $66.90M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$66.90M–
FY2024Dec 31, 2024-$253.64M–
FY2023Dec 31, 2023-$298.42M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$39.72M-171.8%
Q2 FY2026Jun 30, 2026$6.40M+8.5%
Q1 FY2026Mar 31, 2026$22.53M–
Q4 FY2025Dec 31, 2025$39.69M–
Q3 FY2025Sep 30, 2025$55.33M–
Q2 FY2025Jun 30, 2025$5.90M–
Q1 FY2025Mar 31, 2025-$34.03M–
Q4 FY2024Dec 31, 2024-$41.21M–
Q3 FY2024Sep 30, 2024-$71.26M–

More Caris Life Sciences figures

See a number that looks wrong?